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Background: The anti-cyclic citrullinated peptide (CCP) test has a high sensitivity and specificity for
rheumatoid arthritis, although CCP is not the physiological target of the autoantibodies. Citrullinated fibrin
is abundant in inflamed synovium
Objective: To assess the diagnostic and prognostic value of antibodies against citrullinated fibrinogen
(ACF), a soluble precursor of fibrin, in comparison with IgM-rheumatoid factor (IgM-RF) and the second
generation anti-CCP test.
Methods: In 379 patients with early arthritis (258 rheumatoid and 121 undifferentiated), the sensitivity,
specificity, and positive predictive value of ACF, anti-CCP, and IgM-RF for diagnosing rheumatoid arthritis
were calculated. Multivariate logistic regression analysis was used to assess the diagnostic and prognostic
value (radiographic progression after two years) of the tests.
Results: The sensitivities of the ACF, anti-CCP, and IgM-RF tests were 55.8%, 57.8%, and 44.6%, with
specificities of 92.6%, 94.2%, and 96.7%, respectively. Approximately 30% of the IgM-RF negative
patients were positive for ACF or anti-CCP or both. The ACF and anti-CCP test had a high agreement in
early arthritis (k=0.84). Of all baseline characteristics, the ACF test and the anti-CCP test were the best
predictors for diagnosing rheumatoid arthritis at one year (odds ratio (OR) = 10.3 and 10.6, respectively)
and for radiographic progression after two years (OR =12.1 and 14.8).
Conclusions: ACF is as sensitive as anti-CCP and more sensitive than IgM-RF in diagnosing rheumatoid
arthritis in early arthritis. The ACF test is also a good predictor of radiographic progression, with a
performance similar to the anti-CCP test. The ACF test and the anti-CCP test are especially valuable in IgM-
RF negative arthritis.
R
heumatoid arthritis is a systemic autoimmune disease of
unknown origin. To prevent joint destruction, early
diagnosis and treatment is required. The diagnosis can
be made by the 1987 classification criteria of the American
College of Rheumatology (ACR),1 but these criteria have a
low sensitivity in early arthritis.2
There are a few rheumatoid arthritis specific antibodies.
These include the so called antiperinuclear factor (APF), anti-
filaggrin antibodies (AFA), and antikeratin antibodies
(AKA). The epitopes recognised by APF, AFA, and AKA were
found to be generated by a post-translational modification—
namely deimination of the natural amino acid arginine to the
amino acid citrulline by activity of peptidylarginine deimi-
nase.3 Based on that knowledge, Schellekens and co-workers
developed an enzyme linked immunosorbent assay (ELISA)
using a cyclic citrullinated peptide (CCP) derived from the
sequence of human filaggrin as substrate.4 The assay was
later improved (the second generation anti-CCP test) and
sensitivities of 70–80% at specificities of 98–99% have been
reported in established rheumatoid arthritis and controls.5 6
Sensitivity in early arthritis cohorts for the diagnosis
rheumatoid arthritis varies between 40% and 70%.4 7–11
Although the anti-CCP ELISA has a reasonable sensitivity,
the cyclic citrullinated peptide is not the physiological target
of the autoantibodies.
Citrulline containing antigens are expressed in rheumatoid
arthritis synovium.12 13 Moreover, B cells that actively secrete
anti-CCP are specifically present in bone marrow and
synovial fluid of anti-CCP seropositive patients with rheu-
matoid arthritis.14 15 When searching for the nature of
citrullinated proteins in rheumatoid synovial tissue,
Masson-Bessie`re et al identified citrullinated a and b chains
of fibrin as the target for APF, AFA, or AKA positive sera.16
Subsequently, antibodies to in vitro citrullinated fibrinogen, a
soluble precursor of fibrin, have been described as a
serological criterion for the early diagnosis of rheumatoid
arthritis when compared with rheumatoid factor (RF) and
the first generation anti-CCP assay.17
To study the diagnostic and prognostic value of anti-
citrullinated fibrinogen (ACF) in early arthritis in comparison
with IgM-RF and the second generation anti-CCP test, two
studies were undertaken: a cross sectional analysis of
patients with established rheumatoid arthritis and non-
rheumatoid controls, and a diagnostic and prognostic study
on patients from an early arthritis clinic (EAC).
METHODS
Patients
To calculate the cut off values of the ACF test, anti-CCP test,
and the IgM-RF test at 99% specificity, the following groups
of patients were tested: 239 established cases of rheumatoid
Abbreviations: ACF, antibodies to citrullinated human fibrinogen; ACR,
American College of Rheumatology; AFA, anti-filaggrin antibodies;
AKA, antikeratin antibodies; APF, antiperinuclear factor; CCP, cyclic
citrullinated peptide; DAS28, 28 joint disease activity score; DMARD,
disease modifying anti-rheumatic drug; EAC, early arthritis clinic; HAQ,
health assessment questionnaire; RF, rheumatoid factor; ROC, receiver
operating characteristic; VAS, visual analogue scale
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arthritis (53 active and 186 in clinical remission), 91
rheumatology clinic patients without arthritis, and 91
healthy controls. The rheumatoid patients fulfilled the ACR
criteria for rheumatoid arthritis.1 These calculated cut off
values were then used to study the diagnostic and prognostic
value of the ACF test in comparison with the IgM-RF and
anti-CCP tests in a study population.
This study population consisted of 379 consecutive patients
aged >18 years, with peripheral arthritis of two or more
joints and a symptom duration of two years or more; they
were referred to the EAC of the Jan van Breemen Institute, a
large rheumatology clinic in Amsterdam, between 1995 and
1998. Patients who had previously been treated with a
disease modifying anti-rheumatic drug (DMARD) and those
with spondylarthropathy, reactive arthritis, crystal induced
arthropathy, systemic lupus erythematosus, Sjo¨gren’s syn-
drome, or osteoarthritis were excluded. The diagnosis of
rheumatoid arthritis after one year follow up was made in
258 patients by an experienced rheumatologist (BD), who
was blinded to the results of the ACF and anti-CCP tests. The
remaining 121 non-rheumatoid patients were classified as
having undifferentiated arthritis (73 with polyarthritis and
48 with oligoarthritis).
Disease indices
The following data were collected during the first visit:
demographic characteristics, disease duration, disease activ-
ity by disease activity score (DAS28),18 pain by visual
analogue scale (VAS), and functional status by the health
assessment questionnaire (HAQ).19 Laboratory assessments
at baseline included erythrocyte sedimentation rate (ESR), C
reactive protein, IgM-RF, ACF, and anti-CCP. Radiographs of
hands and feet were obtained at baseline and after two years.
The number of erosions and the joint space narrowing were
scored according to the Sharp/van der Heijde method20 by an
experienced rheumatologist (DvS), who was blinded to all
baseline variables.
Antibody measurements
Antibodies to CCP were measured using the second genera-
tion immunoscan rheumatoid arthritis ELISA kit (Euro-
diagnostica, Arnhem, Netherlands, cut off value 25 AU/ml).
The assay was carried out according to the manufacturer’s
protocol. IgM-RF was measured on an ES300 immunochem-
istry analyser (Roche Diagnostics, Almere, Netherlands) as
described before.10
IgG antibodies to citrullinated fibrinogen were detected by
ELISA using citrullinated fibrinogen as immunosorbent.17
Plasminogen-free fibrinogen (Calbiochem, Breda,
Netherlands) was depleted of IgG using protein G sepharose.
IgG-free fibrinogen was citrullinated in vitro using rabbit
skeletal muscle peptidylarginine deiminase (PAD) (Sigma,
Zwijndrecht, Netherlands): 7 U/mg fibrinogen in 0.1 M Tris-
HCl (pH 7.4), 10 mM CaCl2, and 5 mM DTT for two hours at
37 C˚.21 Citrullination was controlled by a mobility shift of a
and b chain of fibrinogen detected by SDS gel electrophoresis
followed by western blotting with a positive serum.16
Microtitre plates (MaxiSorp, Nunc, Roskilde, Denmark)
coated with citrullinated fibrinogen (10 mg/ml phosphate
buffered saline (PBS)) were incubated for one hour at room
temperature with diluted sera in duplicate (1:50 in PBS, 0.2%
gelatine, 0.05% (vol/vol) Tween 20). After incubation with
horseradish peroxidase conjugated mouse monoclonal anti-
human IgG (MH16MIXME, Sanquin, Amsterdam,
Netherlands) for one hour at room temperature, 3,39,5,59
tetramethylbenzidine (10 mg/ml in DMSO) 1:100 diluted in
0.11 M acetate buffer pH 5.5 supplemented with 10 ml/10 ml
of a 3% H2O2 solution was added. The reaction was stopped
with 2M H2SO4 and absorbance at 450 nm was measured. All
washing steps were carried out with PBS, 0.1% Tween 20. The
antibody titre is expressed in AU/ml using a pool of IgM-RF
positive sera as calibrator in eight dilutions. Coefficients of
intra-assay and interassay variation were below 20% both for
the same batch of citrullinated fibrinogen and for different
batches.
Nissinen et al reported that a majority of patients with
recent onset rheumatoid arthritis and 44% of SLE patients
were positive in an anti-PAD ELISA.22 Because the PAD
enzyme used to citrullinate fibrinogen is not removed from
the antigen preparation, antibodies to PAD might influence
the results. This is, however, unlikely, as we did not find
positive reactions with SLE sera.
Data analysis
First, in the group of established rheumatoid arthritis
patients and controls, the area under the receiver operating
characteristic (ROC) curve of ACF, anti-CCP, and IgM-RF
was calculated and the sensitivities of the tests were
compared at three specificities (95%, 98.5%, and 99%). The
cut off value of the three tests was calculated at 99%
specificity. These values were used in the other statistical
analyses.
Second, sensitivity, specificity, and positive predictive value
(PPV) of ACF, anti-CCP, and IgM-RF were calculated in the
group of 379 early arthritis patients. Sensitivity expresses the
percentage of rheumatoid patients positive for the test, while
specificity is calculated from the percentage of test negative
patients with undifferentiated arthritis. The baseline char-
acteristics of the rheumatoid patients and the patients with
undifferentiated arthritis were compared using Student’s t
test, the Mann–Whitney U test, and the x2 test, as
appropriate.
Finally, multivariate logistic regression analysis was used
to assess the diagnostic and prognostic value of the ACF test
in patients with early arthritis. The diagnostic value of the
test was assessed by predicting the diagnosis of rheumatoid
arthritis or undifferentiated arthritis at a one year follow up,
while the prognostic value was assessed by predicting
radiographic progression at two years of follow up.
Radiographic progression was defined as an increase in the
Table 1 Sensitivity of IgM-RF, anti-CCP, and ACF in patients with established rheumatoid
arthritis and controls
Test
Specificity
Area under ROC
curve Confidence interval95% 98.5% 99%
IgM-RF 49.8% 45.2% 41.8% 0.726 0.678 to 0.774
Anti-CCP 72.0% 71.1% 71.1%` 0.903 0.873 to 0.932*
ACF 72.4% 67.8% 67.8%1 0.893 0.861 to 0.925*
*p,0.05 v IgM-RF.
Cut off values of the tests: IgM-RF, 45 IU/ml; `anti-CCP, 25 U/ml; 1ACF, 140 U/ml.
ACF, antibodies to citrullinated human fibrinogen; CCP, cyclic citrullinated peptide; RF, rheumatoid factor; ROC,
receiver operating characteristic.
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Sharp/van der Heijde score by at least 5 after two years follow
up,23 those with smaller increases being classified as not
progressive. Variables associated with the diagnosis of
rheumatoid arthritis in the univariate analysis (p,0.10)
were entered into the models as independent variables. The
analyses were carried out with a backward logistic regression
analysis in SPSS 11.5.
RESULTS
The basic characteristics of the ACF test, the anti-CCP test,
and the IgM-RF test in the patients with established
rheumatoid arthritis and the controls are given in table 1.
At a specificity of 99%, the sensitivities of the ACF test and
the anti-CCP test were 67.8% and 71.1%, respectively. At this
specificity, the IgM-RF test was only 41.8% sensitive. As a
control for ACF, IgG depleted fibrinogen was coated at 10 mg/
ml and the ELISA was carried out as described above.
Subtracting the extinction obtained from the fibrinogen coat
from that of citrullinated fibrinogen before calculation did
not influence the specificity and sensitivity (data not shown).
Cut off values of the tests at 99% specificity were 140 U/ml
for ACF, 25 U/ml for anti-CCP, and 45 IU/ml for IgM-RF. To
compare all tests at the same specificity, these high cut off
values were chosen for further analysis in an early arthritis
population.
Table 2 shows the baseline characteristics of that popula-
tion. The group of patients with rheumatoid arthritis was
significantly older (p,0.01), had higher mean ESR and C
reactive protein levels (p,0.001), a higher mean DAS
(p,0.001), a higher median radiographic damage score
(p,0.01), and a worse mean HAQ (p,0.001) than the group
of patients with undifferentiated arthritis.
The sensitivity, specificity, and PPV for the diagnosis of
rheumatoid arthritis of the tests described are shown in
table 3. Sensitivities varied between 44.6% and 57.8%, and
specificities between 92.6% and 96.7%. About 30% of the
IgM-RF negative early arthritis patients were positive for ACF
or anti-CCP or both. The ACF and anti-CCP tests had a very
high agreement in early arthritis. ACF and anti-CCP were
single positive in 29 of 379 patients (k=0.84, data not
shown); 16 patients were single positive for anti-CCP (81.3%
rheumatoid arthritis) and 13 patients were single positive for
ACF (61.5% rheumatoid arthritis).
Complete two year follow up data were available from 296
of the 379 early arthritis patients (78.1%). These patients
used a median of one DMARD (range one to five) during the
period of follow up; 62% of the patients used methotrexate.
The reasons for loss to follow up were: non-compliance
(n=31); discharge from the clinic because of remission
(n=17); moving home (n=10); death (n=9); and mis-
cellaneous reasons (n=16). The group of patients lost to
follow up had similar baseline characteristics as the group
which completed the follow up, except for the median
baseline Sharp/van der Heijde score which was higher in non-
completers than in completers (6 v 1, p,0.001). Also, the
non-completers were less often positive for IgM-RF (18.1% v
35.1%), anti-CCP (25.6% v 45.1%), or ACF (26.8% v 43.7%)
(p,0.01 for all tests) than the completers.
In the univariate analysis, all baseline variables were
significantly associated with the diagnosis of rheumatoid
arthritis at one year (p,0.05, data not shown). Variables
predictive of the diagnosis of rheumatoid arthritis in the
logistic regression analysis were anti-CCP, IgM-RF, ACF,
DAS28, and VAS pain (table 4). Because of the very high
agreement between the ACF test and the anti-CCP test, two
alternative predictive models were calculated with the same
independent variables, but one without anti-CCP and one
without ACF (data not shown). In the model without anti-
CCP, the ACF test was the best predictor of diagnosis
rheumatoid arthritis (odds ratio (OR)=10.3; 95% confidence
interval (CI), 3.9 to 26.7) and in the model without ACF, the
anti-CCP predicted diagnosis rheumatoid arthritis best
(OR=10.6; 95% CI, 4.1 to 27.8).
Baseline variables with a significant association with
radiographic progression at two years of follow up were
ACF, anti-CCP, IgM-RF, ESR, C reactive protein, DAS28,
HAQ, and the Sharp/van der Heijde score (p,0.001, data not
shown). Variables predictive of radiographic progression in
the logistic regression analysis were anti-CCP, ESR, and the
Sharp/van der Heijde score at baseline, with anti-CCP as the
best predictor (OR=14.8) (table 5). The ACF test was
removed by this model, owing to the very high agreement
between the ACF test and the anti-CCP test. Thus a second
model for predicting radiographic progression was calculated
without anti-CCP as an independent variable (table 6). In
this model, ACF, ESR, and the Sharp/van der Heijde score at
baseline were most predictive of radiographic progression,
with the ACF test as the best predictor (OR=12.1).
Table 2 Baseline characteristics of the early arthritis population, separated into
rheumatoid arthritis (RA) and undifferentiated arthritis (UA)
Baseline characteristics Total group (n = 379) RA (n = 258) UA (n = 121) p Value
Age (years) 56.1 (15.6) 57.6 (14.8) 52.8 (16.6) *
Female (n (%))` 260 (68.6) 181 (70.2) 79 (65.3) NS
Disease duration (years)1 0.4 (0.3 to 0.7) 0.4 (0.3 to 0.7) 0.4 (0.3 to 0.6) NS
ESR (mm/h) 31.8 (22.8) 36.1 (23.2) 22.8 (19.0) **
C reactive protein (mg/dl)1 15 (4 to 35) 18.5 (6.3 to 44) 6 (2 to 18) **
DAS28 score 4.8 (1.3) 5.2 (1.2) 4.1 (1.2) **
Sharp/van der Heijde score1 1 (0 to 6) 2 (0 to 6) 0 (0 to 4) *
HAQ score 1.0 (0.8) 1.2 (0.8) 0.8 (0.6) **
Value are mean (SD) or median (interquartile range).
*p,0.01; **p,0.001.
Student’s t test; `x2 test; 1Mann–Whitney U test.
Table 3 Sensitivity, specificity, and positive predictive
value (PPV) of ACF, anti-CCP, and IgM-RF for the clinical
diagnosis of rheumatoid arthritis in early arthritis
Sensitivity (%) Specificity (%) PPV (%)
Early arthritis (n = 379)
IgM-RF >45 44.6 96.7 96.6
ACF >140 55.8 92.6 94.1
Anti-CCP >25 57.8 94.2 95.5
IgM-RF negative early arthritis (n = 260)
ACF >140 28.7 94.9 87.2
Anti-CCP >25 30.8 96.6 91.7
ACF, antibodies to citrullinated human fibrinogen; CCP, cyclic
citrullinated peptide; RF, rheumatoid factor; ROC, receiver operating
characteristic.
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DISCUSSION
The diagnostic and prognostic value of antibodies directed
against citrullinated fibrinogen was compared with that of
the second generation anti-CCP test in an early arthritis
cohort. For diagnosing rheumatoid arthritis, the ACF test was
as sensitive as the second generation anti-CCP test and more
sensitive than the IgM-RF test. About 30% of the IgM-RF
negative patients with early arthritis were positive for the
ACF test and therefore this test will be useful, especially in
IgM-RF negative early arthritis patients.
Despite the higher sensitivity of the ACF test and the
second generation anti-CCP test compared with the IgM-RF
test for diagnosing rheumatoid arthritis, the specificity of the
IgM-RF test was slightly higher. This reflects a small
percentage of patients diagnosed with undifferentiated
arthritis and having autoantibodies to citrullinated proteins.
Such patients could eventually develop rheumatoid arthritis,
as has been suggested by the high positive predictive value of
anti-CCP in a prospective study of patients with early
arthritis.24 In an earlier study in the same cohort, Jansen et
al found a sensitivity of 42.6% and a specificity of 97.5% for
the first generation anti-CCP test.10 In this early arthritis
population, both the ACF test and the second generation
anti-CCP test were more sensitive for the diagnosis rheuma-
toid arthritis. In an early rheumatoid population, Nogueira et
al found a sensitivity for antibodies to citrullinated fibrinogen
of 64.6% at 98.5% specificity,25 which is in line with the
results of the present study. In multivariate analysis, we
found that the anti-CCP test was the best predictor of the
diagnosis rheumatoid arthritis, followed by the IgM-RF test
and the ACF test (odds ratios around 4.5). Because of the
high agreement of ACF and anti-CCP, it will not be useful to
combine the two tests to predict the diagnosis of rheumatoid
arthritis. Therefore, two other models were calculated with
the same independent variables, but with only one of the two
tests. In these models, baseline ACF and anti-CCP were
similarly good predictors of the diagnosis rheumatoid
arthritis one year later, with odds ratios of approximately
10.5.
The prognostic value of the ACF test was evaluated with
multivariate logistic regression analyses using two year
follow up data. ACF was a good predictor of radiographic
progression at the two year follow up, nearly as good as the
anti-CCP test (OR=12.1 v 14.8). Compared with previous
reports on the prognostic value of citrulline specific auto-
antibodies, including the first and second generation anti-
CCP test, an odds ratio of 12–14 is remarkably high.8 11 26–28
The baseline characteristics of the non-completers were
similar to those of the completers, except for the Sharp/van
der Heijde score and the three antibody tests. The non-
completers had a higher median Sharp/van der Heijde score
than the completers at baseline, although they were positive
less often for IgM-RF, anti-CCP, and ACF. There may have
been a coincidental selection of patients with a high Sharp/
van der Heijde score at baseline, and a subsequent mild
course of the disease, resulting in remission and loss to follow
Table 4 Results of logistic regression analysis of baseline variables to predict rheumatoid
arthritis at one year in early arthritis
B SE
Odds ratio
(Exp(B)) 95% CI Accuracy
Constant 23.355 0.622
78.0%
Anti-CCP >25 1.536 0.587 4.6 1.5 to 14.7
IgM-RF >45 1.521 0.662 4.6 1.3 to 16.7
ACF >140 1.443 0.614 4.2 1.3 to 14.1
DAS28 0.800 0.145 2.2 1.7 to 3.0
Pain (VAS) 20.014 0.007 0.99 0.97 to 0.99
Variables not in
equation
p value
Age 0.204
ESR 0.484
C reactive protein 0.089
HAQ 0.371
Sharp/van der Heijde 0.611
ACF, antibodies to citrullinated human fibrinogen; CCP, cyclic citrullinated peptide; CI, confidence interval;
DAS28, 28 joint disease activity score; HAQ, health assessment questionnaire; RF, rheumatoid factor; ROC,
receiver operating characteristic; VAS, visual analogue scale.
Table 5 Results of logistic regression analysis of baseline variables to predict
radiographic progression at two years in early arthritis
B SE
Odds ratio
(Exp(B)) 95% CI Accuracy
Constant 23.468 0.438
80.2%
Anti-CCP >25 2.694 0.364 14.8 7.2 to 30.2
Sharp/van der Heijde 0.102 0.029 1.1 1.0 to 1.2
ESR 0.024 0.007 1.02 1.01 to 1.04
Variables not in equation p value
IgM-RF >45 0.376
ACF >140 0.099
DAS28 0.412
C reactive protein 0.616
HAQ 0.481
ACF, antibodies to citrullinated human fibrinogen; CCP, cyclic citrullinated peptide; CI, confidence interval;
DAS28, 28 joint disease activity score; HAQ, health assessment questionnaire; RF, rheumatoid factor; ROC,
receiver operating characteristic; VAS, visual analogue scale.
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up. As the Sharp/van der Heijde score predicts radiographic
progression, the selective loss to follow up may have led to an
overestimation of the odds ratios of the anti-CCP test and the
ACF test in predicting radiographic progression in our early
arthritis population.
The results of this study underline the high disease
specificity for antibodies to citrullinated proteins and
peptides. However, the present data provide no explanation
of how the antibody response develops in rheumatoid
arthritis. There was no difference in sensitivity between the
anti-CCP test and the ACF test in early arthritis and in
established rheumatoid arthritis. In the vast majority of
patients both ACF and anti-CCP were found. ACF and anti-
CCP were both single positive in 8% of EAC patients. The
agreement between the tests is surprising as citrullinated
fibrin (fibrinogen is the soluble precursor of fibrin) has been
described as a physiological substrate for antibodies recog-
nising citrulline containing epitopes.16 As has been shown for
several other autoimmune disorders (reviewed by Doyle and
Mamula29), antibodies might preferentially recognise a
modified physiological target—that is, citrullinated fibrin—
early in the disease. Later the antibody response could spread
towards less restricted epitopes.30 Responses to uncitrulli-
nated fibrinogen could be detected in our study population
and were higher in patients than controls. However, they
never reached the degree of positivity that was found with
citrullinated fibrinogen. It is known that rheumatoid arthritis
specific antibodies can be detected several years before the
onset of clinical symptoms.31–33 Although the participants
from the EAC in Amsterdam had a short disease duration at
the time of testing for ACF and anti-CCP, differences
between the two responses might be difficult to detect. The
ACF response in patient samples taken before clinical signs of
the disease could shed light on how the antibody response
develops. Alternatively, other citrullinated proteins—for
example, vimentin—might trigger the initial immune
response in rheumatoid arthritis.5 Citrulline containing
peptides, derived from the sequence of vimentin, have been
shown to be efficiently presented by the rheumatoid arthritis
associated HLA-DRB1*0401 MHC class II molecule to T cells
in a transgenic mouse model.34 The data point towards an
important role of citrulline as an anchor amino acid. Whether
the overall sequence might be of less importance has to be
elucidated in further studies.
In conclusion, the ACF test is useful for establishing the
diagnosis of rheumatoid arthritis and is a good predictor of
radiographic progression in early arthritis, comparable to the
second generation anti-CCP test. Both tests are especially
valuable in IgM-RF negative early arthritis.
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